EQRx
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
EQRx, Inc. was a Cambridge, Massachusetts biopharmaceutical company with a mission to develop and deliver innovative medicines at dramatically lower prices. Led by president and CEO Melanie Nallicheri, its portfolio held more than ten programs — small molecules and biologics, five at clinical stage — targeting chronic and life-threatening conditions.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Business reset
After the unsuccessful development of sugemalimab left no commercially viable path, EQRx executed a large business reset, cutting about 50% of its staff.
- Acquisition agreement
On August 1, 2023, Revolution Medicines signed a definitive agreement to acquire EQRx in an all-stock transaction intended to add more than $1 billion in net cash to Revolution's balance sheet.
- Acquisition completed
On November 9, 2023, Revolution Medicines closed the acquisition; EQRx stock ceased trading on Nasdaq and all EQRx programs were wound down.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.